Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1217683 | 0.92 | CYP1A2 (0.80) | CYP1A2FFAR1KEAP1FFAR4CYP2D6 | |
| SCHEMBL30403190 | 0.92 | CYP1A2 (0.80) | CYP1A2FFAR1KEAP1FFAR4CYP2D6 | |
| SCHEMBL12889161 | 0.92 | CYP1A2 (0.59) | CYP1A2FFAR1KEAP1FFAR4KDM4E | |
| SCHEMBL151952 | 0.90 | HCAR2 (0.57) | CYP1A2FFAR1KEAP1FFAR4 | |
| SCHEMBL29921611 | 0.90 | HCAR2 (0.57) | CYP1A2FFAR1KEAP1FFAR4 | |
| Hydrochloric Acid SCHEMBL27401796 | 0.90 | CYP1A2 (0.77) | CYP1A2FFAR1KEAP1FFAR4CYP2D6 | |
| SCHEMBL5593881 | 0.90 | CYP1A2 (0.72) | CYP1A2FFAR1KEAP1FFAR4CYP2D6 | |
| SCHEMBL17996742 | 0.89 | FFAR1 (0.57) | CYP1A2FFAR1FFAR4 | |
| SCHEMBL30350669 | 0.89 | CYP1A2 (0.56) | CYP1A2FFAR1KEAP1FFAR4 | |
| SCHEMBL19510977 | 0.89 | CYP1A2 (0.56) | CYP1A2FFAR1KEAP1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799496-B2 | Naphthylenyl compounds for long-acting injectable compositions and related methods | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-10-13 | — | — | US | disclosed |
| US-10799496-B2 | Naphthylenyl compounds for long-acting injectable compositions and related methods | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-10-13 | — | — | US | disclosed |
| WO-2020012248-A1 | NOVEL NAPHTHYLENYL COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020012248-A1 | NOVEL NAPHTHYLENYL COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-01-16 | — | — | WO | disclosed |
| US-5093370-A | Useful prior to insertion of tracheotomy tube or discission | TOBISHI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1992-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799496-B2 | Naphthylenyl compounds for long-acting injectable compositions and related methods | OPRL1, OPRK1, OPRM1 | CYP1A2 66/4885FFAR1 2647/4885KEAP1 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.